Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Date : 10/31/2018 @ 8:10PM
Source : Edgar (US Regulatory)
Stock : Keryx Biopharmaceuticals, Inc. (delisted) (KERX)
Quote : 3.36  0.0 (0.00%) @ 1:00AM

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filed by Keryx Biopharmaceuticals, Inc.

Pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12

of the Securities Exchange Act of 1934

Subject Corporation:

Keryx Biopharmaceuticals, Inc.

Commission File No.: 000-30929

 

LOGO

NASDAQ: AKBA NASDAQ: KERX Merger of Equals to Create a Financially Stronger Company Focused on the Development and Commercialization of Therapeutics for Patients with Chronic Kidney Disease “Strategic rationale is compelling.” Ed Arce, H.C. Wainwright “[We] think the combination makes good strategic sense long term.” Christopher Raymond, Piper Jaffray “Akebia and Keryx merger has clear VWUDWHJLF_Æ“W_DQG_VQHUJLHV_Ő Jason Butler, JMP Securities “Keryx and Akebia to merge building an integrated company with pipeline upside.” Reni Benjamin, Raymond James “The combination of the two companies makes strong strategic sense.” Matthew Kaplan, Ladenburg Thalmann Permission to use quotations neither sought nor obtained.


LOGO

WHO IS OUR PROPOSED MERGER PARTNER, AKEBIA? $NHELD_7KHUDSHXWLFV_LV_D_ELRSKDUPDFHXWLFDO_FRPSDQ_IRFXVHG_RQ_GHYHORSLQJ_DQG_FRPPHUFLDOL]LQJ_QRYHO WKHUDSHXWLFV_IRU_SDWLHQWV_EDVHG_RQ_KSR[LD_LQGXFLEOH_IDFWRU_ELRORJ__ZLWK_D_IRFXV_RQ_SDWLHQWV_ZLWK_UHQDO_GLVHDVH__ WHAT IS THE RECOMMENDATION OF THE KERYX BOARD OF DIRECTORS? 7KH_.HU[_%RDUG_RI_‘LUHFWRUV_XQDQLPRXVO_EHOLHYHV_WKH_SURSRVHG_FRPELQDWLRQ_ZLWK_$NHELD_SURYLGHV_VXEVWDQWLDO_ VWUDWHJLF__Æ“QDQFLDO_DQG_RSHUDWLRQDO_EHQHÆ“WV_WR_.HU[_DQG_LWV_VKDUHKROGHUV__ 7KH_FRPELQHG_FRPSDQ_ZLOO_KDYH_D_IXOO_LQWHJUDWHG_EXVLQHVV__ZLWK_ERWK_GHYHORSPHQW_DQG_FRPPHUFLDO_ FDSDELOLWLHV__D_VWURQJ_EDODQFH_VKHHW__DQG_D_FRPSOHWH__ZHOO_UHVSHFWHG_H[HFXWLYH_WHDP__7KH_%RDUG_EHOLHYHV_WKH combination with Akebia materially reduces the risks associated with being a single product company and SURYLGHV_.HU[_VKDUHKROGHUV_ZLWK_D_VXEVWDQWLDO_XSVLGH_RSSRUWXQLW_E_SDUWLFLSDWLQJ_LQ_WKH_SRWHQWLDO_VXFFHVV_RI_ $NHELDōV_ODWH_VWDJH_GUXJ_GHYHORSPHQW_SURJUDP__ZKLFK_DLPV_WR_DGGUHVV_D_PXOWL_ELOOLRQ_GROODU_PDUNHW_RSSRUWXQLW_ 1RWDEO__.HU[ōV_ODUJHVW_VKDUHKROGHU__%DXSRVW_*URXS_6HFXULWLHV__/_/_&___VXSSRUWV_WKH_PHUJHU_DQG_KDV_DJUHHG_WR YRWH_LWV_VKDUHV_LQ_IDYRU_RI_WKH_FRPELQDWLRQ__(DFK_PHPEHU_RI_WKH_%RDUG_LV_DOVR_H[SHFWHG_WR_YRWH_KLV_RU_KHU_VKDUHV LQ_IDYRU_RI_WKH_SURSRVHG_WUDQVDFWLRQ_ $IWHU_PRUH_WKDQ_VL[_PRQWKV_RI_HYDOXDWLRQ_DQG_QHJRWLDWLRQ__WKH_.HU[_%RDUG_XQDQLPRXVO_DQG_HQWKXVLDVWLFDOO VXSSRUWV_WKH_SURSRVHG_PHUJHU_ZLWK_$NHELD_DQG_HQFRXUDJHV_RX_WR_YRWH_FOR this transaction at the upcoming 6SHFLDO_0HHWLQJ_RI_.HU[_6WRFNKROGHUV_RQ_‘HFHPEHU__________ HOW IS THIS PROPOSED MERGER EXPECTED TO ENHANCE MY INVESTMENT? Cr ating e de in Ch o ic Kid e Dise se Th r ie COMBINED COMPANY • Established U.S. sales and Core Fully integrated capabilities marketing infrastructure Capabilities and Successful to bring novel compounds • Medical affairs group R&D expertise through development to Infrastructure • Strong reputation in commercialization nephrology community A phase III, investigational FDA-approved drug Auryxia® (ferric citrate), an Products and oral drug for anemia of generating revenue and FDA-approved medication chronic kidney disease a pipeline of promising, Pipeline in two chronic kidney and other compounds innovative compounds for disease related indications under development future growth Fully staffed executive Management • 125+ US sales force and Successful and well-and functional teams, with sales and marketing leaders respected CEO, CFO and and Team wide range of experience • No permanent CEO renal leadership team and success Financial $49.5 million* $402.1 million* $451.6 million* pro forma Resources (6/30) cash and cash equivalents cash and cash equivalents cash and cash equivalents


LOGO

WHO WILL LEAD THE COMBINED COMPANY? The ombined om any ill be led b an e peri nced exec tive e m ith u ma hed xpertis in e n phrology i du t y John P. Butler Jason A. Amello 3UHVLGHQW_DQG_&KLHI_([HFXWLYH_2IÆ“FHU 693__&KLHI_)LQDQFLDO_2IÆ“FHU_DQG_7UHDVXUHU • 0U__%XWOHU_KDV_QHDUO_WZR_GHFDGHV_RI_H[HFXWLYH_ • 0U__$PHOOR_KDV_VLJQLÆ“FDQW_H[SHULHQFH_LQ_WKH_UHQDO H[SHULHQFH_LQ_WKH_FRPPHUFLDO_UHQDO_WKHUDSHXWLF_Æ“HOG and biopharmaceutical industry • )RUPHU_OHDGHU_RI_*HQ]PH_&RUSRUDWLRQōV • 3UHYLRXVO_KHOG_YDULRXV_SRVLWLRQV_DW_=LRSKDUP renal business 2QFRORJ__*HQ]PH_&RUSRUDWLRQ__DQG_‘HORLWWH Michel Dahan Tamara Dillon Nicole R. Hadas Rita Jain, M.D. Karen Tubridy, SVP, Chief Business SVP, Chief Human SVP, General Counsel SVP, Chief Medical Pharm.D. 2IÆ“FHU Resources 2IÆ“FHU & Secretary 2IÆ“FHU SVP, Chief ‘HYHORSPHQW_2IÆ“FHU HOW WILL THE MERGER IMPACT KERYX’S FINANCIAL PROFILE? $452M >$250M Combined company’s pro forma ,Q_SRWHQWLDO_FRVW_VDYLQJV FDVK_DQG_FDVK_HTXLYDOHQWV_DV_RI_ RYHU_WKH_QH[W_Æ“YH_HDUV -XQH___________XQDXGLWHG_ WHAT ARE THE EXPERTS SAYING? “We believe Keryx’s growing “Our Keryx/Akebia merger “This combination revenue base from Auryxia model indicates the new offers greater combined with its commercial company is worth ~$13/share — scale and growth infrastructure focused on the This represents ~40% upside potential, while nephrology space… strongly to the sum of the KERX and addressing issues complements Akebia’s renal- AKBA valuations… pre the on both sides.” focused late-stage pipeline merger announcement.” Ed Arce, and its R&D organization.” H.C. Wainwright <LJDO_1RFKRPRYLW]_ Matthew Kaplan, Citi Ladenburg Thalmann Permission to use quotations neither sought nor obtained.


LOGO

WHAT ELSE DO I NEED TO KNOW? PROPOSED • Stock for stock merger TRANSACTION • Each share of Keryx will be converted TERMS into 0.37433 shares of Akebia 7+(_.(5<;_ & CLOSING • Expected to close by the end of 2018 %2$5’_85*(6_ • Keryx shareholders to own approximately OWNERSHIP 50.6% of the pro forma company and <28_72_927(_ Akebia shareholders to own approximately 49.4%, on a fully diluted basis ŏ)25Õ_7+(_ • CEO to come from Akebia GOVERNANCE • The Board is expected to consist of 10 0(5*(5_ directors, drawn from both companies and a new independent Chairperson 352326$/6 WHEN CAN I VOTE? HOW DO I VOTE? r t e c d . f i i t ti $OO_YRWHV_PXVW_EH_UHFHLYHG_E 3OHDVH_QRWH_RX_ZLOO_UHFHLYH_D_OHWWHU_RI_WUDQVPLWWDO ______S_P___8_6__(DVWHUQ_7LPH_ XQGHU_VHSDUDWH_FRYHU_LQ_WKH_FRPLQJ_ZHHNV__<RXU_VKDUH RQ_‘HFHPEHU__________ FHUWLÆ“FDWH_GRHV_QRW_QHHG_WR_EH_UHWXUQHG_LPPHGLDWHO_ Additional Information and Where to Find It ŏSURMHFW_Ő_ ŏLQWHQG_Ő_ ŏEHOLHYH_Ő_ ŏPD_Ő_ ŏZLOO_Ő_ ŏVKRXOG_Ő_ ŏSODQ_Ő_ ŏFRXOG_Ő_ ŏWDUJHW_Ő_ ŏFRQWHPSODWH_Ő_ ŏHVWLPDWH_Ő_ ,Q_FRQQHFWLRQ_ZLWK_WKH_SURSRVHG_PHUJHU__$NHELD_KDV_Æ“OHG_ZLWK_WKH_6(&_D_5HJLVWUDWLRQ_6WDWHPHQW_RQ_)RUP_ ŏSRVLWLRQ_Ő_ŏSUHGLFW_Ő_ŏSRWHQWLDO_Ő_ŏRSSRUWXQLWŐ_DQG_ZRUGV_DQG_WHUPV_RI_VLPLODU_VXEVWDQFH_XVHG_LQ_FRQQHFWLRQ_ 6____ZKLFK__DV_DPHQGHG__LQFOXGHV_D_Æ“QDO_SURVSHFWXV_ZLWK_UHVSHFW_WR_WKH_VKDUHV_RI_$NHELDōV_FRPPRQ_VWRFN_WR ZLWK_DQ_GLVFXVVLRQ_RI_IXWXUH_SODQV__DFWLRQV_RU_HYHQWV_LGHQWLI_IRUZDUG_ORRNLQJ_VWDWHPHQWV__$OO_VWDWHPHQWV__ EH_LVVXHG_LQ_WKH_SURSRVHG_PHUJHU_DQG_D_GHÆ“QLWLYH_MRLQW_SUR[_VWDWHPHQW_RI_.HU[_DQG_$NHELD_ZLWK_UHVSHFW_WR other than historical facts, including statements regarding the ability of the parties to complete the merger WKH_SURSRVHG_PHUJHU__7KH_5HJLVWUDWLRQ_6WDWHPHQW_ZDV_GHFODUHG_HIIHFWLYH_E_WKH_6(&_RQ_2FWREHU__________ FRQVLGHULQJ_WKH_YDULRXV_FORVLQJ_FRQGLWLRQV__WKH_FRQVXPPDWLRQ_RI_WKH_0HUJHU_DQG_WKH_SRWHQWLDO_EHQHÆ“WV_RI_WKH DQG_WKH_GHÆ“QLWLYH_MRLQW_SUR[_VWDWHPHQW_ZDV_PDLOHG_RU_RWKHUZLVH_PDGH_DYDLODEOH_WR_.HU[ōV_DQG_$NHELDōV_ merger are forward looking statements. Important factors that could cause actual results to differ materially UHVSHFWLYH_VWRFNKROGHUV_RQ_RU_DERXW_2FWREHU___________%()25(_0$.,1*_$1<_927,1*_’(&,6,21__$.(%,$ō6_ IURP_$NHELDōV_DQG_.HU[ōV_SODQV__HVWLPDWHV_RU_H[SHFWDWLRQV_FRXOG_LQFOXGH__EXW_DUH_QRW_OLPLWHG_WR___L__$NHELD_RU $1’_ .(5<;ō6_5(63(&7,9(_ 6+$5(+2/’(56_ $5(_ 85*(‘_ 72_ 5($’_ 7+(_ -2,17_ 352;<_ 67$7(0(17_ .HU[_PD_EH_XQDEOH_WR_REWDLQ_VWRFNKROGHU_DSSURYDO_DV_UHTXLUHG_IRU_WKH_PHUJHU___LL__FRQGLWLRQV_WR_WKH_FORVLQJ_ 35263(&786_,1_,76_(17,5(7<_$1’_$1<_27+(5_‘2&80(176_),/(‘_%<_($&+_2)_$.(%,$_$1’_.(5<;_ RI_WKH_PHUJHU_PD_QRW_EH_VDWLVÆ“HG___LLL__WKH_PHUJHU_PD_LQYROYH_XQH[SHFWHG_FRVWV__OLDELOLWLHV_RU_GHODV___LY__WKH :,7+_7+(_6(&_,1_&211(&7,21_:,7+_7+(_352326(‘_0(5*(5_25_,1&25325$7(‘_%<_5()(5(1&( HIIHFW_RI_WKH_DQQRXQFHPHQW_RI_WKH_PHUJHU_RQ_WKH_DELOLW_RI_$NHELD_RU_.HU[_WR_UHWDLQ_DQG_KLUH_NH_SHUVRQQHO_ 7+(5(,1_ %(&$86(_ 7+(<_ :,//_ &217$,1_ ,03257$17_ ,1)250$7,21_ $%287_ 7+(_ 352326(‘ DQG_PDLQWDLQ_UHODWLRQVKLSV_ZLWK_FXVWRPHUV__VXSSOLHUV_DQG_RWKHUV_ZLWK_ZKRP_$NHELD_RU_.HU[_GRHV_EXVLQHVV__RU 75$16$&7,21_$1’_7+(_3$57,(6_72_7+(_352326(‘_75$16$&7,21__,QYHVWRUV_DQG_VKDUHKROGHUV_DUH_DEOH_ RQ_$NHELDōV_RU_.HU[ōV_RSHUDWLQJ_UHVXOWV_DQG_EXVLQHVV_JHQHUDOO___Y__$NHELDōV_RU_.HU[ōV_UHVSHFWLYH_EXVLQHVVHV_ WR_REWDLQ_D_IUHH_FRS_RI_WKH_MRLQW_SUR[_VWDWHPHQW_SURVSHFWXV_DQG_RWKHU_GRFXPHQWV_FRQWDLQLQJ_LPSRUWDQW PD_VXIIHU_DV_D_UHVXOW_RI_XQFHUWDLQW_VXUURXQGLQJ_WKH_PHUJHU_DQG_GLVUXSWLRQ_RI_PDQDJHPHQWōV_DWWHQWLRQ_GXH LQIRUPDWLRQ_DERXW_$NHELD_DQG_.HU[__ZLWK_WKH_6(&__WKURXJK_WKH_ZHEVLWH_PDLQWDLQHG_E_WKH_6(&_DW_ZZZ_VHF_ WR_WKH_PHUJHU___YL__WKH_RXWFRPH_RI_DQ_OHJDO_SURFHHGLQJV_UHODWHG_WR_WKH_PHUJHU___YLL__$NHELD_RU_.HU[_PD_EH_ JRY__$NHELD_DQG_.HU[_PDNH_DYDLODEOH_IUHH_RI_FKDUJH_DW_ZZZ_DNHELD_FRP_DQG_ZZZ_NHU[_FRP__UHVSHFWLYHO DGYHUVHO_DIIHFWHG_E_RWKHU_HFRQRPLF__EXVLQHVV__DQG_RU_FRPSHWLWLYH_IDFWRUV___YLLL__WKH_RFFXUUHQFH_RI_DQ_HYHQW_ _LQ_WKH_ŏ,QYHVWRUVŐ_VHFWLRQ___FRSLHV_RI_PDWHULDOV_WKH_Æ“OH_ZLWK__RU_IXUQLVK_WR__WKH_6(&__ FKDQJH_RU_RWKHU_FLUFXPVWDQFHV_WKDW_FRXOG_JLYH_ULVH_WR_WKH_WHUPLQDWLRQ_RI_WKH_PHUJHU_DJUHHPHQW___L[__ULVNV_WKDW_ WKH_PHUJHU_GLVUXSWV_FXUUHQW_SODQV_DQG_RSHUDWLRQV_DQG_WKH_SRWHQWLDO_GLIÆ“FXOWLHV_LQ_HPSORHH_UHWHQWLRQ_DV_D Participants in the Solicitation UHVXOW_RI_WKH_PHUJHU___[__WKH_ULVN_WKDW_$NHELD_RU_.HU[_PD_EH_XQDEOH_WR_REWDLQ_JRYHUQPHQWDO_DQG_UHJXODWRU $NHELD__.HU[_DQG_WKHLU_UHVSHFWLYH_GLUHFWRUV__H[HFXWLYH_RIÆ“FHUV_DQG_FHUWDLQ_HPSORHHV_DQG_RWKHU_SHUVRQV_ DSSURYDOV_UHTXLUHG_IRU_WKH_WUDQVDFWLRQ__RU_WKDW_UHTXLUHG_JRYHUQPHQWDO_DQG_UHJXODWRU_DSSURYDOV_PD_GHOD PD_EH_GHHPHG_WR_EH_SDUWLFLSDQWV_LQ_WKH_VROLFLWDWLRQ_RI_SUR[LHV_IURP_WKH_VKDUHKROGHUV_RI_$NHELD_DQG_.HU[_ WKH_WUDQVDFWLRQ_RU_UHVXOW_LQ_WKH_LPSRVLWLRQ_RI_FRQGLWLRQV_WKDW_FRXOG_UHGXFH_WKH_DQWLFLSDWHG_EHQHÆ“WV_IURP_WKH in connection with the proposed merger. Security holders may obtain information regarding the names, SURSRVHG_WUDQVDFWLRQ_RU_FDXVH_WKH_SDUWLHV_WR_DEDQGRQ_WKH_SURSRVHG_WUDQVDFWLRQ___[L__ULVNV_WKDW_WKH_DQWLFLSDWHG_ DIÆ“OLDWLRQV_DQG_LQWHUHVWV_RI_$NHELDōV_GLUHFWRUV_DQG_RIÆ“FHUV_LQ_$NHELDōV_$QQXDO_5HSRUW_RQ_)RUP____._IRU_WKH_ EHQHÆ“WV_RI_WKH_PHUJHU_RU_RWKHU_FRPPHUFLDO_RSSRUWXQLWLHV_PD_RWKHUZLVH_QRW_EH_IXOO_UHDOL]HG_RU_PD_WDNH Æ“VFDO_HDU_HQGHG_‘HFHPEHU___________ZKLFK_ZDV_Æ“OHG_ZLWK_WKH_6(&_RQ_0DUFK__________DQG_LWV_GHÆ“QLWLYH_ ORQJHU_WR_UHDOL]H_WKDQ_H[SHFWHG___[LL__WKH_LPSDFW_RI_OHJLVODWLYH__UHJXODWRU__FRPSHWLWLYH_DQG_WHFKQRORJLFDO SUR[_VWDWHPHQW_IRU_WKH______DQQXDO_PHHWLQJ_RI_VKDUHKROGHUV__ZKLFK_ZDV_Æ“OHG_ZLWK_WKH_6(&_RQ_$SULO___________ FKDQJHV__LQFOXGLQJ_WKH_UHFHQW_FKDQJHV_WR_UHLPEXUVHPHQW_FRYHUDJH_IRU_$XU[LD_WKDW_FRXOG_KDYH_D_PDWHULDO 6HFXULW_KROGHUV_PD_REWDLQ_LQIRUPDWLRQ_UHJDUGLQJ_WKH_QDPHV__DIÆ“OLDWLRQV_DQG_LQWHUHVWV_RI_.HU[ōV_GLUHFWRUV DGYHUVH_HIIHFW_RQ_$XU[LD_VDOHV_DQG_SURÆ“WDELOLW___[LLL__H[SHFWDWLRQV_IRU_IXWXUH_FOLQLFDO_WULDOV__WKH_WLPLQJ_DQG DQG_RIÆ“FHUV_LQ_.HU[ōV_$QQXDO_5HSRUW_RQ_)RUP____._IRU_WKH_Æ“VFDO_HDU_HQGHG_‘HFHPEHU___________ZKLFK_ZDV_ SRWHQWLDO_RXWFRPHV_RI_FOLQLFDO_WULDOV_DQG_LQWHUDFWLRQV_ZLWK_UHJXODWRU_DXWKRULWLHV__DQG__[LY__RWKHU_ULVNV_WR_WKH Æ“OHG_ZLWK_WKH_6(&_RQ_)HEUXDU___________DQG_WKH_$PHQGPHQW_1R____RQ_)RUP____._$__ZKLFK_ZDV_Æ“OHG_ZLWK FRQVXPPDWLRQ_RI_WKH_PHUJHU__LQFOXGLQJ_WKH_ULVN_WKDW_WKH_PHUJHU_ZLOO_QRW_EH_FRQVXPPDWHG_ZLWKLQ_WKH_H[SHFWHG_ WKH_6(&_RQ_$SULO___________DQG_LWV_GHÆ“QLWLYH_SUR[_VWDWHPHQW_IRU_WKH______DQQXDO_PHHWLQJ_RI_VKDUHKROGHUV__ WLPH_SHULRG_RU_DW_DOO__$GGLWLRQDO_IDFWRUV_WKDW_PD_DIIHFW_WKH_IXWXUH_UHVXOWV_RI_$NHELD_DQG_.HU[_DUH_VHW_IRUWK_LQ_ ZKLFK_ZDV_Æ“OHG_ZLWK_WKH_6(&_RQ_0D___________7R_WKH_H[WHQW_WKH_KROGLQJV_RI_$NHELDōV_VHFXULWLHV_E_$NHELDōV WKHLU_UHVSHFWLYH_Æ“OLQJV_ZLWK_WKH_6(&__LQFOXGLQJ_HDFK_RI_$NHELDōV_DQG_.HU[ōV_PRVW_UHFHQWO_Æ“OHG_$QQXDO_5HSRUW GLUHFWRUV_DQG_H[HFXWLYH_RIÆ“FHUV_RU_WKH_KROGLQJV_RI_.HU[_VHFXULWLHV_E_.HU[ōV_GLUHFWRUV_DQG_H[HFXWLYH_RIÆ“FHUV RQ_)RUP____.__VXEVHTXHQW_4XDUWHUO_5HSRUWV_RQ_)RUP____4__&XUUHQW_5HSRUWV_RQ_)RUP___.__LQ_WKH_GHÆ“QLWLYH KDYH_FKDQJHG_VLQFH_WKH_DPRXQWV_VHW_IRUWK_LQ_$NHELDōV_RU_.HU[ōV_UHVSHFWLYH_SUR[_VWDWHPHQW_IRU_LWV_____ MRLQW_SUR[_VWDWHPHQW_SURVSHFWXV_Æ“OHG_E_$NHELD_DQG_.HU[_DQG_RWKHU_Æ“OLQJV_ZLWK_WKH_6(&__ZKLFK_DUH_DYDLODEOH_ DQQXDO_PHHWLQJ_RI_VKDUHKROGHUV__VXFK_FKDQJHV_KDYH_EHHQ_RU_ZLOO_EH_UHŴHFWHG_RQ_6WDWHPHQWV_RI_&KDQJH_LQ RQ_WKH_6(&ōV_ZHEVLWH_DW_ZZZ_VHF_JRY__6HH_LQ_SDUWLFXODU_ŏ5LVN_)DFWRUVŐ_LQ_WKH_MRLQW_SUR[_VWDWHPHQW_SURVSHFWXV__ 2ZQHUVKLS_RQ_)RUP___Æ“OHG_ZLWK_WKH_6(&__$GGLWLRQDO_LQIRUPDWLRQ_UHJDUGLQJ_WKH_LQWHUHVWV_RI_VXFK_LQGLYLGXDOV_LQ_ ,WHP__$_RI_$NHELDōV_4XDUWHUO_5HSRUW_RQ_)RUP____4_IRU_WKH_TXDUWHU_HQGHG_-XQH__________XQGHU_WKH_KHDGLQJ WKH_SURSRVHG_PHUJHU_DUH_LQFOXGHG_LQ_WKH_MRLQW_SUR[_VWDWHPHQW_SURVSHFWXV_UHODWLQJ_WR_WKH_SURSRVHG_PHUJHU ŏ5LVN_)DFWRUVŐ_DQG_,WHP__$_RI_.HU[ōV_4XDUWHUO_5HSRUW_RQ_)RUP____4_IRU_WKH_TXDUWHU_HQGHG_-XQH_________ WKDW_ZDV_Æ“OHG_ZLWK_WKH_6(&__7KHVH_GRFXPHQWV_PD_EH_REWDLQHG_IUHH_RI_FKDUJH_IURP_WKH_6(&ōV_ZHEVLWH_DW_ZZZ_ XQGHU_WKH_KHDGLQJ_ŏ5LVN_)DFWRUV_Ő_7KH_ULVNV_DQG_XQFHUWDLQWLHV_GHVFULEHG_DERYH_DQG_LQ_$NHELDōV_PRVW_UHFHQW_ VHF_JRY__$NHELDōV_ZHEVLWH_DW_ZZZ_DNHELD_FRP_DQG_.HU[ōV_ZHEVLWH_DW_ZZZ_NHU[_FRP__ 4XDUWHUO_5HSRUW_RQ_)RUP____4_DQG_.HU[ōV_PRVW_UHFHQW_4XDUWHUO_5HSRUW_RQ_)RUP____4_DUH_QRW_H[FOXVLYH_ 7KLV_GRFXPHQW_GRHV_QRW_FRQVWLWXWH_D_VROLFLWDWLRQ_RI_SUR[__DQ_RIIHU_WR_SXUFKDVH_RU_D_VROLFLWDWLRQ_RI_DQ_RIIHU_WR_ DQG_IXUWKHU_LQIRUPDWLRQ_FRQFHUQLQJ_$NHELD_DQG_.HU[_DQG_WKHLU_UHVSHFWLYH_EXVLQHVVHV__LQFOXGLQJ_IDFWRUV_WKDW sell any securities. SRWHQWLDOO_FRXOG_PDWHULDOO_DIIHFW_WKHLU_UHVSHFWLYH_EXVLQHVVHV__Æ“QDQFLDO_FRQGLWLRQ_RU_RSHUDWLQJ_UHVXOWV__PD_ Forward-Looking Statements HPHUJH_IURP_WLPH_WR_WLPH__5HDGHUV_DUH_XUJHG_WR_FRQVLGHU_WKHVH_IDFWRUV_FDUHIXOO_LQ_HYDOXDWLQJ_WKHVH_IRUZDUG_ looking statements, and not to place undue reliance on any forward-looking statements. Readers should also This document contains forward-looking statements within the meaning of the federal securities law. Such FDUHIXOO_UHYLHZ_WKH_ULVN_IDFWRUV_GHVFULEHG_LQ_RWKHU_GRFXPHQWV_WKDW_$NHELD_DQG_.HU[_Æ“OH_IURP_WLPH_WR_WLPH_ VWDWHPHQWV_DUH_EDVHG_XSRQ_FXUUHQW_SODQV__HVWLPDWHV_DQG_H[SHFWDWLRQV_WKDW_DUH_VXEMHFW_WR_YDULRXV_ULVNV_DQG_ with the SEC. The forward-looking statements in these materials speak only as of the date of these materials. uncertainties. The inclusion of forward-looking statements should not be regarded as a representation ([FHSW_DV_UHTXLUHG_E_ODZ__$NHELD_DQG_.HU[_DVVXPH_QR_REOLJDWLRQ_WR_XSGDWH_RU_UHYLVH_WKHVH_IRUZDUG_ORRNLQJ WKDW_VXFK_SODQV__HVWLPDWHV_DQG_H[SHFWDWLRQV_ZLOO_EH_DFKLHYHG__:RUGV_VXFK_DV_ŏDQWLFLSDWH_Ő_ŏFUHDWH_Ő_ŏH[SHFW_Ő VWDWHPHQWV_IRU_DQ_UHDVRQ__HYHQ_LI_QHZ_LQIRUPDWLRQ_EHFRPHV_DYDLODEOH_LQ_WKH_IXWXUH_


Additional Information and Where to Find It

In connection with the proposed merger, Akebia has filed with the SEC a Registration Statement on Form S-4, which, as amended, includes a final prospectus with respect to the shares of Akebia’s common stock to be issued in the proposed merger and a definitive joint proxy statement of Keryx and Akebia with respect to the proposed merger. The Registration Statement was declared effective by the SEC on October 30, 2018 and the definitive joint proxy statement was mailed or otherwise made available to Keryx’s and Akebia’s respective stockholders on or about October 31, 2018. BEFORE MAKING ANY VOTING DECISION, AKEBIA’S AND KERYX’S RESPECTIVE SHAREHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF AKEBIA AND KERYX WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and shareholders will be able to obtain a free copy of the joint proxy statement/prospectus and other documents containing important information about Akebia and Keryx, with the SEC, through the website maintained by the SEC at www.sec.gov. Akebia and Keryx make available free of charge at www.akebia.com and www.keryx.com, respectively (in the “Investors” section), copies of materials they file with, or furnish to, the SEC.

Participants in the Solicitation

Akebia, Keryx and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the shareholders of Akebia and Keryx in connection with the proposed merger. Security holders may obtain information regarding the names, affiliations and interests of Akebia’s directors and officers in Akebia’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which was filed with the SEC on March 12, 2018 and its definitive proxy statement for the 2018 annual meeting of shareholders, which was filed with the SEC on April 30, 2018. Security holders may obtain information regarding the names, affiliations and interests of Keryx’s directors and officers in Keryx’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which was filed with the SEC on February 21, 2018, and the Amendment No. 1 on Form 10-K/A, which was filed with the SEC on April 30, 2018, and its definitive proxy statement for the 2018 annual meeting of shareholders, which was filed with the SEC on May 31, 2018. To the extent the holdings of Akebia’s securities by Akebia’s directors and executive officers or the holdings of Keryx securities by Keryx’s directors and executive officers have changed since the amounts set forth in Akebia’s or Keryx’s respective proxy statement for its 2018 annual meeting of shareholders, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed merger are included in the joint proxy statement/prospectus relating to the proposed merger that was filed with the SEC. These documents may be obtained free of charge from the SEC’s website at www.sec.gov, Akebia’s website at www.akebia.com and Keryx’s website at www.keryx.com.

This document does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the federal securities law. Such statements are based upon current plans, estimates and expectations that are subject to various risks and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “create,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “target,”


“contemplate,” “estimate,” “position,” “predict,” “potential,” “opportunity” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding the ability of the parties to complete the merger considering the various closing conditions; the consummation of the Merger and the potential benefits of the merger are forward looking statements. Important factors that could cause actual results to differ materially from Akebia’s and Keryx’s plans, estimates or expectations could include, but are not limited to: (i) Akebia or Keryx may be unable to obtain stockholder approval as required for the merger; (ii) conditions to the closing of the merger may not be satisfied; (iii) the merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement of the merger on the ability of Akebia or Keryx to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Akebia or Keryx does business, or on Akebia’s or Keryx’s operating results and business generally; (v) Akebia’s or Keryx’s respective businesses may suffer as a result of uncertainty surrounding the merger and disruption of management’s attention due to the merger; (vi) the outcome of any legal proceedings related to the merger; (vii) Akebia or Keryx may be adversely affected by other economic, business, and/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (ix) risks that the merger disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger; (x) the risk that Akebia or Keryx may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xi) risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, competitive and technological changes, including the recent changes to reimbursement coverage for Auryxia that could have a material adverse effect on Auryxia sales and profitability; (xiii) expectations for future clinical trials, the timing and potential outcomes of clinical trials and interactions with regulatory authorities; and (xiv) other risks to the consummation of the merger, including the risk that the merger will not be consummated within the expected time period or at all. Additional factors that may affect the future results of Akebia and Keryx are set forth in their respective filings with the SEC, including each of Akebia’s and Keryx’s most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, in the definitive joint proxy statement/prospectus filed by Akebia and Keryx and other filings with the SEC, which are available on the SEC’s website at www.sec.gov. See in particular “Risk Factors” in the joint proxy statement/prospectus, Item 1A of Akebia’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 under the heading “Risk Factors” and Item 1A of Keryx’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 under the heading “Risk Factors.” The risks and uncertainties described above and in Akebia’s most recent Quarterly Report on Form 10-Q and Keryx’s most recent Quarterly Report on Form 10-Q are not exclusive and further information concerning Akebia and Keryx and their respective businesses, including factors that potentially could materially affect their respective businesses, financial condition or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that Akebia and Keryx file from time to time with the SEC. The forward-looking statements in these materials speak only as of the date of these materials. Except as required by law, Akebia and Keryx assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

 

2

Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.

Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Intraday Stock Chart

Today : Monday 14 October 2019

Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.

Latest KERX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.